Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Grabs License to Genetic Technologies Non-Coding DNA Patent

NEW YORK, April 23-Biochip company Nanogen has secured a license from the Australian firm Genetic Technologies Limited for access to non-coding DNA analysis patents, the companies said yesterday.


The license, which took effect April 12, is not exclusive, and is limited to human research and diagnostics.


Genetic Technologies said that Nanogen is paying the company cash and securities worth approximately A$620,000 (US $334,207) as an issue fee for the license.


Genetic Technologies recently granted a much broader license to Sequenom for its non-coding DNA patents, and is currently in discussions with other major United States biotech companies.


The company, which is based in Melbourne, boasts Australia's largest DNA paternity testing lab. In addition, it holds a range of international patents on non-coding (intron) DNA analysis and non-coding genomic mapping.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.